GLPG 0259
Alternative Names: GLPG0259Latest Information Update: 02 Oct 2021
At a glance
- Originator Galapagos NV
- Class Antirheumatics; Small molecules
- Mechanism of Action MAP-kinase-activated kinase 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 09 Nov 2011 Efficacy & adverse events data from a phase II trial in Rheumatoid arthritis presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2011)
- 15 Apr 2011 Discontinued - Phase-II for Rheumatoid arthritis in Belgium (PO)
- 15 Apr 2011 Discontinued - Phase-II for Rheumatoid arthritis in Netherlands (PO)